Evidence map›Paper›PMID 18362936›Full record

ArticleBritish journal of cancer2008

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.

J Wei, Z Zou, X Qian, Y Ding, L Xie, J J Sanchez, Y Zhao, J Feng, Y Ling, Y Liu and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  3. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  4. Trial
  5. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2009
    Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Personalized medicine and the clinical laboratory.Einstein (Sao Paulo, Brazil) · 2014
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

J WeiDepartment of Oncology, Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Medical School of Nanjing University, Nanjing 210008, China.
Z Zou
X Qian
Y Ding
L Xie
J J Sanchez
Y Zhao
J Feng
Y Ling
Y Liu
L Yu
R Rosell
B Liu
Nanjing Drum Tower Hospital · CNInstitut Català d'Oncologia · ESJiangsu Cancer Hospital · CNNanjing Medical University · CNUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum chemotherapy. Excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were assessed in advanced gastric cancer tumour samples using real-time quantitative PCR in 76 patients treated with a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen. Median survival time in patients with low ERCC1 levels was significantly longer than in those with high levels (15.8 vs 6.2 months; P<0.0001). Patients with high TS levels had longer survival than those with low levels (12.2 vs 10.1 months; P=0.01). Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1 months (P<0.0001). The hazard ratio for patients with high ERCC1 expression was 9.4 (P<0.0001). In patients with high mRNA levels of ERCC1, alternative chemotherapy regimens should be considered.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDNA-Binding ProteinsEndonucleasesFemaleFluorouracilHumansLeucovorinMaleMiddle AgedMultivariate AnalysisOrganoplatinum CompoundsPolymerase Chain ReactionRNA, MessengerDNA-Binding ProteinsEndonucleasesERCC1 protein, humanFluorouracilLeucovorinOrganoplatinum CompoundsRNA, MessengerThymidylate Synthase

Identifiers

PMID18362936
PMCPMC2361707
OpenAlexW2012550724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.